Article Text

PDF
Letter
Efficacy of glutamine in postinfection IBS
  1. Alexander Charles Ford1,2,
  2. Peter R Gibson3
  1. 1Leeds Gastroenterology Institute, St James’s University Hospital, Leeds, UK
  2. 2Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, UK
  3. 3Department of Gastroenterology, Alfred Health and Monash University, Melbourne, Victoria, Australia
  1. Correspondence to Professor Alexander Charles Ford, Leeds Gastroenterology Institute, St. James’s University Hospital, Leeds LS9 7TF, UK; alexf12399{at}yahoo.com

Statistics from Altmetric.com

We read the randomised controlled trial (RCT) by Zhou et al.1 The authors recruited a highly selected group of patients with increased intestinal permeability and postinfection IBS with diarrhoea (IBS-D), defined by an unconfirmed enteric infection in the 12 months prior to symptom onset, and randomised them to 8 weeks of treatment with either glutamine or placebo. The population screened also had other curious features. For example, only four had rapid orocaecal transit on lactulose hydrogen breath testing, erroneously described as small intestinal bacterial overgrowth. This appears low, compared with other studies examining this issue in patients with IBS.

There are other minor issues with the trial conduct and analysis. First, compliance was checked by telephone calls, not a particularly robust method. Second, the efficacy analysis was per-protocol, rather than intention-to-treat, and minimal information on dropouts …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.